Michael McCully

Michael McCully

President and Chief Operating Officer

Michael is the President and Chief Operating Officer of Syndeio Biosciences. An experienced biopharma executive, investor, and entrepreneur, Michael has spent the past 20 years contributing to the development of dozens of successful biotech companies. Michael established his career in the biotech industry in the early 2000s at Recombinant Capital, Inc, a boutique strategic advisory firm, where he served as an advisor to over 100 companies, including emerging and established biopharma, and had a role in more than $4 billion in partnering transactions. In 2008, Recombinant Capital was acquired by Deloitte and Michael became a leader in the Deloitte Life Sciences Practice based in San Francisco.

Since his time at Deloitte, Michael has held operating roles at several emerging and established biopharma companies, notably serving as Head of Business Development, BioNeurology at Elan Pharmaceuticals, Head of Financial Strategy at Coherus Biosciences (CHRS), and Chief Business Officer of the pain-focused specialty pharma Charleston Laboratories where he led the $650M U.S. partnership with Daiichi Sankyo. Most recently, Michael was the Chief Executive Officer of Anagin, Inc., an emerging biotech developing first-in-class novel targeted therapies for pathologies associated with disrupted synaptic plasticity in the central nervous system.

Michael received his B.S. from Purdue University and a hybrid master’s degree from Northwestern University.